Aspen Pharmacare Valuation Multiples

Aspen Pharmacare Overview

About Aspen Pharmacare

Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.

Founded

1985

HQ

Employees

9.6K

Website

aspenpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: $569M

EV

$5B

Valuation Multiples

Multiples.vc

Start free trial

Aspen Pharmacare Financials

Aspen Pharmacare reported last 12-month revenue of $3B and EBITDA of $569M.

In the same LTM period, Aspen Pharmacare generated $1B in gross profit, $569M in EBITDA, and $234M in net income.

Aspen Pharmacare P&L

In the most recent fiscal year, Aspen Pharmacare reported revenue of $3B and EBITDA of $371M.

Aspen Pharmacare expects next 12-month revenue of XXX and NTM EBITDA of XXX

Aspen Pharmacare Stock Performance

Aspen Pharmacare has current market cap of $4B, and enterprise value of $5B.

Aspen Pharmacare's stock price is $8.12.

Aspen Pharmacare Valuation Multiples

Aspen Pharmacare trades at 2.1x EV/Revenue multiple, and 9.3x EV/EBITDA.

Aspen Pharmacare Financial Valuation Multiples

As of April 18, 2026, Aspen Pharmacare has market cap of $4B and EV of $5B.

Equity research analysts estimate Aspen Pharmacare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Aspen Pharmacare has a P/E ratio of 15.4x.

Aspen Pharmacare Margins & Growth Rates

Aspen Pharmacare's revenue in the last 12 month declined by (4%).

Aspen Pharmacare's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Aspen Pharmacare's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Aspen Pharmacare's rule of X is 10% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Aspen Pharmacare Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Aspen Pharmacare M&A Activity

Aspen Pharmacare acquired XXX companies to date.

Last acquisition by Aspen Pharmacare was on XXXXXXXX, XXXXX. Aspen Pharmacare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Aspen Pharmacare Investment Activity

Aspen Pharmacare invested in XXX companies to date.

Aspen Pharmacare made its latest investment on XXXXXXXX, XXXXX. Aspen Pharmacare invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).